A detailed history of Sendero Wealth Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Sendero Wealth Management, LLC holds 20,272 shares of NBIX stock, worth $2.53 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares
20,272
Previous 19,735 2.72%
Holding current value
$2.53 Million
Previous $2.72 Million 14.1%
% of portfolio
0.38%
Previous 0.47%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

BUY
$114.58 - $153.15 $61,529 - $82,241
537 Added 2.72%
20,272 $2.33 Million
Q2 2024

Jul 12, 2024

BUY
$130.86 - $143.19 $22,507 - $24,628
172 Added 0.88%
19,735 $2.72 Million
Q1 2024

Apr 16, 2024

SELL
$130.4 - $143.74 $33,121 - $36,509
-254 Reduced 1.28%
19,563 $2.7 Million
Q4 2023

Jan 17, 2024

BUY
$106.07 - $132.76 $28,744 - $35,977
271 Added 1.39%
19,817 $2.61 Million
Q3 2023

Oct 10, 2023

BUY
$94.02 - $117.1 $460,603 - $573,672
4,899 Added 33.45%
19,546 $2.2 Million
Q2 2023

Jul 20, 2023

SELL
$89.53 - $104.87 $136,712 - $160,136
-1,527 Reduced 9.44%
14,647 $1.38 Million
Q1 2023

Apr 27, 2023

BUY
$94.11 - $123.02 $123,095 - $160,910
1,308 Added 8.8%
16,174 $1.64 Million
Q4 2022

Feb 01, 2023

BUY
$106.72 - $127.06 $134,147 - $159,714
1,257 Added 9.24%
14,866 $1.78 Million
Q3 2022

Oct 27, 2022

BUY
$92.03 - $107.81 $69,482 - $81,396
755 Added 5.87%
13,609 $1.45 Million
Q2 2022

Aug 09, 2022

BUY
$75.79 - $100.07 $133,087 - $175,722
1,756 Added 15.82%
12,854 $1.25 Million
Q1 2022

May 06, 2022

SELL
$72.45 - $94.81 $10,939 - $14,316
-151 Reduced 1.34%
11,098 $1.04 Million
Q4 2021

Feb 15, 2022

BUY
$79.65 - $106.22 $895,982 - $1.19 Million
11,249 New
11,249 $958,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Sendero Wealth Management, LLC Portfolio

Follow Sendero Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sendero Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sendero Wealth Management, LLC with notifications on news.